Pfizer stock

For example, in one 30-day period in the late summer of 2006 no fewer than four small companies, Icagen, Corcept, SGX, and Adolor, lost 73%, 56%, 41%, and 45% of their stock values, respectively, in one single day because of bad news on late-stage clinical trials. In contrast, Pfizer stock lost 10.6% of its value (still about 19 billion ) after the company announced that it was discontinuing clinical trials on its most promising candidate, torcetrapib, for safety reasons. 

Jeffrey L. Stock Pfizer Global Research and Development, Pfizer Inc., Genetically Modified Models Center of Emphasis, Groton, CT, USA... 

Arindam Bose (Pfizer Central Research) further discussed the ICH documents and presented a rationale for the recommended combination of test procedures and process clearance validations required to demonstrate that marketed biopharmaceuticals are free of adventitious agents. He showed that testing of Pre-Seed Stock (PSS), the Master Cell Bank (MCB), and the Working Cell Bank (WCB) is required to demonstrate that they are free from contamination by mycoplasma, bacteria, molds, and yeasts. In addition, viral clearance validation studies must be performed on scaled down versions of each chromatographic step and the viral inactivation/removal step employed in the product purification scheme. Finally, clearance studies must be conducted with a panel of relevant and model viruses (typically three to four) to establish that the purification scheme will indeed purge any viruses that may be inadvertently introduced during processing. 

Every day, staffers in Pfizer Inc s treasury office recorded the high, low, and closing prices of only two stocks, in a book that went back to the 1950s their own company, and Merck. 

The stock plunged from nearly 100 at the end of 2000 to the 40s in the summer and early fall of 2002. Merck unexpectedly announced in June 2001 that it would miss its earnings for that year, then followed up in December with the shocker that its earnings for the next year would be flat. On Wall Street, the pressure grew to seek a merger, even as archrival Pfizer swallowed up Warner-Lambert Company, then Pharmacia. 

Seven months after that, with the stock down in the 40s, Emma was still holding on to his Merck shares. But it wasn t based on faith so much any more. The price was just too low now—in fact, the entire market was too depressed—to do any selling. With Pfizer s new merger, I think Merck is going to get left behind rather quickly. I don t know what their strategy is. If I was going to buy anything in the pharmaceutical industry. I d buy Pfizer. ... 

A stock biopolymer solution containing 4,000 ppm biopolymer was prepared for each biopolymer following the procedure recommended by Pfizer Inc. [30]. All solutions were adjusted such that they contained about 5 g/L formaldehyde to inhibit bacterial degradation. The 4,000 ppm stock solutions were filtered using a Whatman number 1 filter paper and were stored in closed polyethylene containers to minimize oxygen uptake. 

---